

# Inducible cAMP Early Repressor Splice Variants ICER I and II $\gamma$ Both Repress Transcription of c-fos and Chromogranin A

Kristine Misund,<sup>1</sup> Tonje S. Steigedal,<sup>1</sup> Astrid Lægreid,<sup>1</sup> and Liv Thommesen<sup>1,2\*</sup>

<sup>1</sup>Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, N-7489 Trondheim, Norway

<sup>2</sup>Department of Food Science and Medical Technology, Sør-Trøndelag University College, Norway

**Abstract** Inducible cAMP early repressor (ICER) splice variants are generated upon activation of an alternative, intronic promoter within the CREM gene. ICER is proposed to downregulate both its own expression, and the expression of other genes, containing cAMP-responsive promoter elements. To examine the biological function of the two ICER splice variants, I and II $\gamma$ , in comparable cellular systems, we generated HEK 293 cell variants with controllable overexpression of either ICER I or II $\gamma$ . These two splice variants contain two different variants of DNA binding domains. Overexpression of either ICER I or II $\gamma$  strongly represses CRE-driven reporter gene transcription but not AP1- or NF $\kappa$ B-driven transcription. Thus, high specificity is maintained even at ICER overexpression. We here show that both ICER I and II $\gamma$  repress Pituitary adenylate cyclase-activating polypeptide (PACAP)-mediated c-fos mRNA induction with similar efficiency, indicating that both splice variants play an important role in modulating PACAP-mediated transcriptional activation of the c-fos gene. ICER I and II $\gamma$  also repress cAMP-mediated activation of chromogranin A (CgA), indicating that these splice variants may function as negative feedback regulators in CgA synthesis. The proliferation rate was not altered in cells overexpressing ICER I or II $\gamma$ . Thus, in the epithelial cells HEK 293, ICER I and II $\gamma$  splice variants seem to exert similar biological function. *J. Cell. Biochem.* 101: 1532–1544, 2007. © 2007 Wiley-Liss, Inc.

**Key words:** ICER; Gene regulation; alternative splicing; transcription factors; CREM; c-fos; CgA

The transcription of many genes is regulated by increased intracellular cAMP levels in response to extracellular stimuli. CREB/CREM/ATF [Rosenberg et al., 2002; Servillo et al., 2002] transcription factors mediate the nuclear response to the cAMP pathway [Mayr and Montminy, 2001]. The CREB/CREM/ATF family comprises homologous proteins which all contain a basic DNA binding domain (DBD) that recognizes a highly conserved sequence known as the cAMP response element (CRE)

[Montminy et al., 1986; Short et al., 1986; Lewis et al., 1987; Bokar et al., 1988; Kim et al., 1993]. The proteins in this family share other characteristics as well: a leucine zipper domain for protein dimerization, a phosphorylation site for modulation of functional activity, and a transactivation domain that interacts with other components of the transcriptional machinery [Mayr and Montminy, 2001; Quinn, 2002; De Cesare et al., 2003]. The CREB and ATF-1 proteins are both expressed ubiquitously, whereas CREM gene products are expressed in a cell-, tissue-, and development-specific manner [De Cesare and Sassone-Corsi, 2000; Mayr and Montminy, 2001]. The CREM gene gives rise to several alternative splice products that encode polypeptides with distinct repressor or activator properties [Foulkes et al., 1991; Delmas et al., 1992; Laoide et al., 1993; Daniel et al., 2000]. Inducible cAMP early repressor (ICER) is transcribed from the intronic CREM gene promoter P2 (Fig. 1), which contains four CRE-like elements and directs the

Grant sponsor: The Norwegian Research Council; Grant number: 10246000.

\*Correspondence to: Liv Thommesen, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Medisinsk Teknisk Senter, N-7489 Trondheim, Norway.  
E-mail: liv.thommesen@ntnu.no

Received 5 October 2006; Accepted 18 December 2006

DOI 10.1002/jcb.21267

© 2007 Wiley-Liss, Inc.




Fig. 1. Schematic representation of the CREM gene with ICER splice variants.

expression of a truncated protein, composed of the basic domain and leucine zipper motif only [Molina et al., 1993]. Thus, in contrast to the other CRE-binding proteins, the principal determinant of ICER activity is its intracellular concentration and not its degree of phosphorylation. Different members of the CREB/CREM/ATF family can form homo- and/or heterodimers and bind to similar DNA binding sites. ICER can form heterodimers with all other CREM proteins as well as with CREB proteins, although ICER homodimer formation is more favored [Molina et al., 1993; Stehle et al., 1993]. ICER containing dimers bind efficiently to CREs and can competitively block DNA binding of CREM activators or other members of the CREB/CREM/ATF family to promoters like, for example, the somatostatin promoter [Stehle et al., 1993] and the insulin promoter [Inada et al., 1999]. Occupation of CRE promoter elements by a dimer containing a repressor isoform results in repression of transcription, presumably due to impaired interaction with the coactivator protein CBP or TFIID or both [Sun and Maurer, 1995; Nakajima et al., 1997]. ICER is subject to an autoregulatory feedback loop since it downregulates its own expression via the CRE-elements in its own promoter [Molina et al., 1993; Foulkes et al., 1996].

Alternative splicing of the  $\gamma$  exon and the two different DNA binding domains DBD I and DBD II generates ICER splice variants I, I $\gamma$ , II, and II $\gamma$  (Fig. 1). The expression of ICER proteins with alternative DBDs raises the possibility that splice variants containing alternative DBDs may show different promoter element sequence specificity or otherwise differ in their modes of action as repressors. Also, the presence or absence of the  $\gamma$  exon may have an effect on ICER function.

The aim of the present study was to elucidate the biological function of ICER I and II $\gamma$  splice variants. We found that both ICER I and II $\gamma$  repress CRE-driven reporter gene transcription as well as c-fos gene expression. This indicates that both ICER I and II $\gamma$  may act as anti-oncogenes inhibiting the expression of growth-related genes. Furthermore, both splice variants repress cAMP-mediated activation of chromogranin A (CgA), indicating that both ICER I and II $\gamma$  may function as modulators of synthesis of this protein known to be ubiquitous and functionally important in the neuroendocrine system [Taupenot et al., 2003].

## MATERIALS AND METHODS

### Cells and Reagents

Flp-In T-REX 293 (human embryo kidney cells, Invitrogen, Carlsbad, CA), were maintained in Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/L glucose, 0.1 mg/ml L-glutamine and 10 U/ml penicillin-streptomycin (GIBCO, Invitrogen) supplemented with 10% fetal calf serum (FCS; Euroclone Ltd, Devon, UK), 100  $\mu$ g/ml Zeocin (Invitrogen) and 15  $\mu$ g/ml Blasticidin (Invitrogen). Forskolin, CPT-cAMP, and phorbol-12-myristate-13-acetate (PMA), were purchased from Sigma Aldrich (St. Louis, MO), Pituitary adenylate cyclase-activating polypeptide (PACAP-38) was obtained from Bachem (Bobendorf, Switzerland) and Human rhTNF $\alpha$  was purchased from R&D Systems (Abingdon, UK). The peptides were dissolved and stored frozen at  $-20^{\circ}\text{C}$ .

### Reporter Assays

pCRELuc containing 4 $\times$  CRE somatostatin consensus promoter elements (TGACGTCA) and pNF $\kappa$ BLuc, containing five copies of the

NF $\kappa$ B enhancer element (TGGGGACTTTCCGC), were obtained from Stratagene (La Jolla, CA). pAP1-Luc containing four tandem copies of the AP1 consensus sequence (TGA(G/C)TCA) were obtained from Clontech (Palo Alto, CA). The plasmid pXp100Luc containing 100 bp of the proximal CgA promoter [Wu et al., 1995] was a generous gift from Dr. Daniel O'Connor (University of California, San Diego, CA). Cells were seeded in 96-well plates ( $4 \times 10^4$  cells/well) or 6-well plates ( $1.3 \times 10^6$  cells/well) and transfected after 24 h. *Transfection in 96-well plates:* 0.24  $\mu$ g luciferase reporter plasmid DNA was transfected by use of 0.8  $\mu$ l Lipofectamine 2000 transfection reagent (Invitrogen). After 4 h the medium was replaced with normal growth medium. Cotransfections of reporter plasmids and siRNA were performed with 0.15  $\mu$ g luciferase reporter plasmid DNA and 0.08  $\mu$ g siRNA by use of 0.8  $\mu$ l XtremeGENE transfection reagent. *Cotransfections in 6-well plates* were performed with 1  $\mu$ g siRNA and 2  $\mu$ g plasmid DNA by use of 10  $\mu$ l XtremeGENE reagent. The next day cells were either harvested for protein isolation (6-well plates), or treated with stimuli (96-well plates) and after 6 h the medium was removed followed by lysis in 20  $\mu$ l of lysis buffer (Promega, Madison, WI). Luciferase activity was measured by Wallac 1420 Victor <sup>3</sup>TM plate reader (Perkin-Elmer Life and Analytical Sciences, Boston, MA) by using the Luciferase Reporter Assay System (Promega).

#### PCR and Real-Time PCR

Total RNA was isolated using RNeasy mini kit (Qiagen, Germantown, MD) (6-well plates) or RNeasy Midi kit (Qiagen) (75 cm<sup>2</sup> bottle) according to the manufactures instruction. cDNA synthesis was performed with 500 ng total RNA in a 10  $\mu$ l reaction containing 1 $\times$  PCR buffer II, 5 mM MgCl<sub>2</sub>, 500  $\mu$ M each dNTP, 2.5  $\mu$ M Oligo d(T) 16 primer, 0.4 U/ $\mu$ l RNase inhibitor and 2.5 U/ $\mu$ l MuLV Reverse transcriptase (Applied Biosystems). cDNA synthesis was performed at 10 min at 25°C followed by 1.5 h at 48°C and 5 min at 95°C. After synthesis, the cDNA was diluted 1:2 with RNase-free water. *Regular PCR* was performed with 1 $\times$  PCR buffer, 0.05 U PLATINUM Taq DNA Polymerase or PLATINUM Taq DNA Polymerase High Fidelity (Invitrogen), 0.5  $\mu$ M of each primer (forward and reverse), 7 mM MgCl<sub>2</sub>, 0.8 mM of each dNTP (Applied Biosystems) in a 20  $\mu$ l

reaction. PCRs were performed in a GeneAmp PCR System 9700 (Applied Biosystems) using the following cycling parameters: activation for 10 min at 94°C followed by 35 cycles at 94°C for 15 s, 61°C for 15 s, and 72°C for 30 s. *TaqMan Real Time PCR* was performed with 1 $\times$  Quantitect Probe PCR Master Mix (Qiagen), 400 nM of each primer, 200 nM TaqMan Probe (Eurogentec, Belgium) and cDNA equivalent to 62.5 ng total RNA in a total reaction volume of 25  $\mu$ l. The Real-Time PCR was performed in Stratagene's Mx3000P Real Time PCR system; 15 min at 95°C, 45 thermal cycles of 15 s at 95°C, 1 min at 56°C, and 30 s at 76°C. Fold induction of gene expression level was estimated by the  $\Delta\Delta$ Ct-method, where: Fold change =  $2^{-\Delta\Delta C_t}$  and  $\Delta\Delta C_t = (C_{t_{GOI}} - C_{t_{GAPDH}})_{untreated} - (C_{t_{GOI}} - C_{t_{GAPDH}})_{treated}$  [Livak and Schmittgen, 2001].

#### Primers and Probe Design

*Regular PCR:* the following PCR primers were used for ICER (Genbank<sup>TM</sup>/EBI Data Bank accession number NM\_182717): ICER-S: 5'-TGGAACACTTTATGTTGAACTGTGG-3'; ICER-AS: 5'-CAGTTCATAGTTAAATATTTCTAGTA-3'. *TaqMan Real Time PCR:* using computer software [GenScript Corp. Real-Time PCR Primer Design] (<http://www.genscript.com/ssl-bin/app/primer>) primers and probes were designed to recognize human CgA (Genbank<sup>TM</sup>/EBI Data Bank accession number NM\_001275), c-fos (Genbank<sup>TM</sup>/EBI Data Bank accession number K00650), and GAPDH (Genbank<sup>TM</sup>/EBI Data Bank accession number NM\_002046) mRNA sequences. The sequences of primers and probes used for TaqMan Real Time PCR analyses are as follows: *CgA-S:* 5'-TACAAGGAGATCCGGAAAGG-3'; *CgA-AS:* 5'-CTCCTCTTTCTGCTGGGAGT-3', *CgA-probe:* 5'-(FAM) TCCACAGCCAGAGCCTCCGA (Dark Quencher)-3', *c-fos-S:* 5'-GGGCAAGG-TGGAACAGTTAT-3'; *c-fos-AS:* 5'-TCCTTCTCCTTCAGCAGGTT-3', *c-fos-probe:* 5'-(FAM) CAGCTCCCTCCTCCGGTTGC (Dark Quencher)-3' and *GAPDH-S:* 5'-GAAGGTGAAGGTTCGGAGTC-3', *GAPDH-AS:* 5'-GAAGATGGTGATGGGATTTTC-3' and *GAPDH-probe:* 5'-(FAM) CAAGCTTCCCGTTCTCAGCC (Dark Quencher)-3'.

#### Gateway Cloning

Oligonucleotide primers for the amplification of ICER DNA fragments were designed with

flanking attB1 or attB2 sites for insertion into the GATEWAY donor vector pDONR201 (Invitrogen). Primers with the following sequences were synthesized by Invitrogen (ICER specific sequence in bold): ICER-S, 5'-attB1-GGGGACAAGTTTGTACAAAAAAGCAGGCTT**GGAACTTTATGTTGAACTGTG-G-3'**; and ICER-AS, 5'-attB2-GGGG ACCACTT-TGTACAAGAAAGCTGGG**TCAGTTCATAG-TTAAATATTTCTAGTA-3'**. The PCR products were cloned directly into pDONR201, and the resulting plasmids were used to transfer the ICER sequences into pcDNA5/FRT/TO-cassetteA [T-Rex Flp-In compatible] via homologous recombination. *Preparation of Gateway compatible T-Rex plasmid:* The T-Rex Flp-In compatible plasmid pcDNA5/FRT/TO (Invitrogen) was digested with EcoRV and purified. The plasmid was ligated to the GATEWAY Reading Frame Cassette A (RfA), obtained from digestion with EcoRV from the RfA-containing plasmid pGEMA (generous gift from Dr. Ole Morten Seternes, University of Tromsø, Norway). The clones obtained represent GATEWAY-compatible "destination vectors" (pcDNA5/FRT/TO-cassetteA). The pDONR201 containing the ICER PCR-products were used to transfer the ICER sequences into the pcDNA5/FRT/TO-cassetteA [T-Rex Flp-In compatible] via homologous recombination. The pcDNA/FRT/TO-ICER plasmids were confirmed by sequencing.

### Stable Cell Lines

Stable cell lines with tetracycline-induced ICER expression were established by transfecting the Flp-In T-Rex 293 cell line with pcDNA5/FRT/TO constructs with the recommended amount of pOG44. Two days post-transfection cells were split (1:8) into 24 well plates. After 6 h growth medium containing 150  $\mu$ g/ml hygromycin and 15  $\mu$ g/ml blasticidin was added. After 19 days individual colonies were picked, tested for Zeocin sensitivity, lack of  $\beta$ -gal activity and tetracycline (Invitrogen) inducible overexpression of the relevant construct by Western analysis.

The resulting variant cell lines were termed "HEK 293<sub>ind</sub>-ICER I" and "HEK 293<sub>ind</sub>-ICER II $\gamma$ " and represent model systems where a specific ICER splice variant can be induced without activating other genes. Flp-In T-Rex

293 cells transfected with empty vector, were termed "HEK 293<sub>ind</sub>-Control."

### siRNA Procedures

siRNA-ICER I, siRNA ICER II $\gamma$ , siRNA-CAT, and siRNA-EGFP (The Biotechnology Centre, University of Oslo [Amarzguioui et al., 2003; Amarzguioui and Prydz, 2004]), were annealed at 10  $\mu$ M in 500  $\mu$ l of 10 mM Tris-HCl, pH 7.4. siRNA-All-ICER (Qiagen), were annealed at 20  $\mu$ M in 1,000  $\mu$ l siRNA suspension buffer (Qiagen). siRNA species were designed targeting sites within human protein ICER: siRNA-ICER I: 5'-GAUGACACAGAUGAGGAAAC-T-3', siRNA-ICER II $\gamma$ : 5'-GAGAUGACACAG-CUGCCACU-GG-3' and siRNA-All-ICER: 5'-CAUUAUGGCUGUAACUGGATT-3'. Control siRNAs used: siRNA-CAT [Mousses et al., 2003]: 5'-GAGUGAAUACCACGACGAUU-3' and siRNA-EGFP [Mousses et al., 2003]: 5'-GCAAGCUGACCCUGAAGUUC-3'.

Luciferase reporter plasmids, Luc-ICER, for control of ICER siRNA efficiency were generated as follows: pGL3-Control vector (Promega) was digested with XbaI, and subsequently filled of recessed 3' termini by Klenow fragment (New England Biolabs, Beverly, MA). The plasmid was ligated to the GATEWAY Reading Frame Cassette A (RfA) with the same procedure as above. The clones obtained represent GATEWAY-compatible "destination vectors" (pGL3-Control-cassetteA), with the cassette inserted following the Luc gene in the pGL3 plasmid. The ICER containing plasmid pDONR201, were used for cloning ICER into GATEWAY compatible pGL3-Control vector via LR reaction following the manufacturer's instructions. pGL3-Luc-ICER constructs were sequenced for control of correct reading frame and orientation.

Specificity of siRNAs were tested in reporter-gene studies using Luc-ICER plasmids, and the siRNAs had all potent and specific inhibitory effects (~80–90%) in the cotransfection assays. The inhibiting effect was confirmed on the protein level (results not shown).

### Western Blotting

Cells were grown in 75 cm<sup>2</sup> flask ( $4 \times 10^6$  cells) or 6-well plates ( $1.3 \times 10^6$  cells) for two days, and then washed with PBS and harvested directly in 2,000  $\mu$ l (500  $\mu$ l for 6-wells) SDS sample-buffer, as described previously [Thommesen et al., 2000], except for 2 h incubation with primary



antibodies (diluted 1:100–1:1,000) and incubation with secondary antibody (1:1,000) for 1 h at room temperature. The following antibodies were used: Rabbit anti-human CREM-1 (X-12) (1:100) (Santa Cruz, CA), Rabbit  $\alpha$ -CAT antiserum (1:5,000) (Invitrogen), rabbit anti-mouse Akt (1:1,000) (Cell Signaling Technology) and horseradish peroxidase conjugated goat anti-rabbit IgG (1:1,000) (Cell Signaling Technology).

### Proliferation Assay

Proliferation rate was determined by measuring DNA synthesis using the Cell proliferation ELISA BrdU (5-bromo-2'-deoxyuridine) kit (Roche). Flp-In T-REX 293 cells ( $2 \times 10^3$ ) were seeded out in 96-well microtiter plates in 100  $\mu$ l serum-containing medium, and after 30 h tetracycline was added to the cells. BrdU-labeling solution (10  $\mu$ l per well) was added 17 h before incorporation of BrdU was measured, and the measurements were done as described previously [Thommesen et al., 2006]. Incorporation of BrdU was measured 2–7 days after cell seeding, and the number of cells was determined (five parallels).

### Sequencing

Cycle sequencing was performed using the Big Dye sequencing kit (Applied Biosystems). Sequencing reactions were analyzed on an ABI377 Prism Sequencer (Perkin-Elmer Life and Analytical Sciences).

### Statistical Analysis

*P*-values were estimated using a student two-tailed *t*-test, assuming unequal variance.

## RESULTS

Previous studies examining the function of one specific ICER splice variant include studies of transgenic mice where increased  $\beta$  cell ICER I $\gamma$  expression leads to development of early severe diabetes [Inada et al., 2004, 2005], and studies using stably transfected ICER II $\gamma$  cells, showing that ICER II $\gamma$  inhibits growth of pituitary tumor cells and choriocarcinoma cells [Lamas et al., 1997; Razavi et al., 1998]. However, most studies of specific ICER variants up until now have been performed using transient transfection, like, for example, studies indicating that ICER II $\gamma$  evokes neuronal apoptosis in cell cultures [Jaworski et al., 2003; Tomita et al., 2003]. Use of transient transfection

does not always guarantee a controlled increase in the protein of interest. We wanted to study the biological effects of specific ICER splice variants in a system where its levels could be determined, and where different ICER splice variants could be examined separately. The aim of this study was to compare the biological response of ICER I and II $\gamma$ , and examine their repressive effect on authentic CRE-containing promoters.


The stable cell lines for inducible ICER splice variant overexpression were termed “HEK 293<sub>ind</sub>-ICER I” and “HEK 293<sub>ind</sub>-ICER II $\gamma$ .” They represent model systems where a specific ICER splice variant can be induced by tetracycline and where ICER levels are normal in the untreated condition.

To verify that ICER protein levels were increased in the tetracycline-induced state, HEK 293<sub>ind</sub> cell variants were treated with tetracycline for different time intervals and ICER protein was analyzed by Western blot analysis. The result shows that both ICER I and II $\gamma$  protein levels are strongly upregulated upon 8 h tetracycline treatment, and that they are increased further upon treatment for 12 h. Furthermore, the high ICER protein levels still persist after 24 h treatment (Fig. 2).

### Inducible ICER I and II $\gamma$ Proteins Repress c-fos mRNA Expression

The c-fos promoter contains, among multiple promoter elements, CRE elements important for c-fos gene expression [Berkowitz et al., 1989; Fisch et al., 1989]. HEK 293 cells were stimulated with the neuroendocrine peptide hormone Pituitary adenylate cyclase-activating polypeptide (PACAP), which induced a five- to eightfold increase in c-fos gene expression (Fig. 3). We here show that overexpression of either ICER I or II $\gamma$  splice variants repress PACAP-induced c-fos gene expression by 60% and 55%, respectively (Fig. 3A,B). Similarly, overexpression of either ICER I or II $\gamma$  repressed forskolin-induced c-fos gene expression by 75% and 60%, respectively (data not shown). Interestingly, basal c-fos expression (uninduced state) was also reduced (30–35%) in cells overexpressing either ICER I or II $\gamma$  (Fig. 3A,B).

Our results indicate that both ICER I and II $\gamma$  repress transcription from an endogenous, CRE-dependent promoter. Furthermore, our results show that both splice variants can interfere both with the forskolin-response,



**Fig. 2.** Western blot verifying ICER overexpression in tetracycline-treated HEK 293<sub>ind</sub>-ICER cells. Whole cell lysates from HEK 293<sub>ind</sub>-ICER I and HEK 293<sub>ind</sub>-ICER II $\gamma$  cells treated with tetracycline (1  $\mu$ g/ml) for 8, 12, and 24 h were analyzed on Western blot using antiserum towards CREM and Akt. HEK 293<sub>ind</sub>-Control (HEK 293 cells transfected with empty vector) treated with tetracycline for 12 h.

which is mediated via the protein kinase A (PKA) signaling pathway, as well as with the transcriptional response to the hormone PACAP, which has been reported to include


both PKA [Kienlen Campard et al., 1997; Vaudry et al., 1998] as well as MAP kinases [Schafer et al., 1996], in its activation of c-fos gene expression.

#### ICER Represses Transcription from the Chromogranin A (CgA) Promoter


We further studied another CRE-containing promoter, the CgA promoter, where the CRE-element is shown to play an indispensable role in expression of the gene [Wu et al., 1995]. Overexpression of ICER I repressed forskolin-activated CgA promoter-driven transcription by approximately 50% in a reporter gene assay (Fig. 4A). ICER I also repressed activation of the CgA promoter by the non-hydrolysable cAMP analogue in CPT-cAMP to a similar manner (data not shown). Similarly, overexpression of ICER II $\gamma$  resulted in about 50% repression of CgA reporter gene activity (Fig. 4B). In order to examine whether expression of the endogenous CgA gene was also repressed, we measured CgA mRNA levels in forskolin-induced cells with and without ICER overexpression. We found that endogenous CgA-gene is expressed at low levels in untreated HEK 293 cells and that overexpression of ICER I completely blocked forskolin-induced expression of the endogenous CgA gene (Fig. 4C). Our results strongly suggest that activation of the endogenous CgA gene is repressed by ICER, which has not been previously reported.

#### Overexpression of ICER Specifically Represses CRE-Driven Gene Expression

To examine whether the ICER splice variants target CRE promoter elements specifically, we tested the effect of ICER I and II $\gamma$  overexpression in reporter gene assays with



**Fig. 3.** Effect of ICER I and II $\gamma$  overexpression on c-fos gene expression. **A:** HEK 293<sub>ind</sub>-ICER I and **(B)** HEK 293<sub>ind</sub>-ICER II $\gamma$  cells were pre-treated with tetracycline (1  $\mu$ g/ml) for 11 h, and treated with PACAP (0.2  $\mu$ M) for 30 min before harvesting. c-fos mRNA expression were determined by quantitative TaqMan real time PCR. Mean  $\pm$  SEM of at least three separate measurements are shown. \*\* $P$  < 0.05, \* $P$  < 0.06; significant difference from tetracycline untreated cells.



**Fig. 4.** Effect of ICER I overexpression on CgA reporter gene and CgA gene expression. **A:** HEK 293<sub>ind</sub>-ICER I and **(B)** HEK 293<sub>ind</sub>-ICER II $\gamma$  cells, were transfected with CgA-reporter gene, pretreated with tetracycline (1  $\mu$ g/ml) for 16 h, and treated with forskolin (10  $\mu$ M) for 6 h. **C:** HEK 293<sub>ind</sub>-ICER I cells pre-treated with tetracycline (1  $\mu$ g/ml) for 11 h, and treated with forskolin (10


$\mu$ M) for 1 h and CgA expression measured by quantitative TaqMan real time PCR. Mean  $\pm$  SEM of at least three measurements are shown for the transfections (A,B), while two biological experiments (with three technical replicas) are shown for the real-time PCR data. \*\* $P < 0.05$ , \* $P < 0.09$ ; significant difference from tetracycline untreated cells.

reportergenes driven by artificial promoters of the isolated promoter elements CRE, AP-1, and NF $\kappa$ B. Experiments with the CRE reporter plasmid pCRELuc showed that overexpression of either ICER I or II $\gamma$  resulted in strong reduction in forskolin-mediated CRE-driven transcription (Fig. 5A,B). Also PACAP-mediated CRE-driven transcription was repressed by overexpression of either ICER I or II $\gamma$  (Fig. 5A,B). The two splice variants inhibited reporter gene activation to a similar extent, and both ICER I and II $\gamma$  repressed basal CRE activity (e.g., reporter gene activity in the absence of stimuli) (Fig. 5A,B).

In order to verify that the observed repressing effect was caused by ICER, the activity of the CRE-driven reporter plasmid was measured in the presence of siRNA towards ICER. We found that siRNA towards ICER clearly reversed the repressing effect of overexpressed ICER on forskolin-induced CRE-driven transcription (Fig. 6). In ICER I overexpressing cells both ICER I specific siRNA as well as siRNA

targeting all ICER splice variants increased CRE-driven transcription (55% and 65%, respectively; Fig. 6A). Similarly, in ICER II $\gamma$  overexpressing cells, both ICER II $\gamma$  specific siRNA as well as all-ICER siRNA increased CRE-driven transcription (60% and 85%, respectively; Fig. 6B). No effect of all-ICER siRNA was observed on forskolin-induced reporter gene activity in the HEK 293<sub>ind</sub>-Control cells (Fig. 6C). These cells were stably transfected with a control DNA-construct that did not contain ICER sequences. These results clearly indicate that the repression of forskolin-induced reporter gene activity is caused by the overexpressed ICER splice variant.

Overexpression of either ICER I or II $\gamma$  had no repressing effect upon either forskolin or PMA-induced AP1 promoter activity (Fig. 7A). Likewise, no effect of either ICER I or II $\gamma$  overexpression was observed on tumor necrosis factor (TNF)-induced activity of the NF $\kappa$ B reporter plasmid (Fig. 7B). These results show that ICER overexpression does not lead to



**Fig. 5.** Effect of ICER overexpression on pCRELuc activity. **A:** HEK 293<sub>ind</sub>-ICER I cells (**B**) HEK 293<sub>ind</sub>-ICER II $\gamma$  cells, and (**C**) HEK 293<sub>ind</sub>-Control cells were transfected with pCRELuc, pretreated with tetracycline (1  $\mu$ g/ml) for 24 h, and treated with forskolin (10  $\mu$ M) for 6 h. Mean  $\pm$  SEM of quintuple measurements are shown. \* $P$  < 0.05; significant difference from tetracycline untreated cells.

general transcriptional repression and that the consensus AP1 and NF $\kappa$ B promoter elements are not affected by ICER I or II $\gamma$ . The fact that CRE-elements (*TGACGTCA*) are repressed but not AP1-elements (*TGA(G/C)TCA*), indicates that high specificity is maintained in the cell system used in the present study even though ICER protein levels are high in the tetracycline-induced state. Overexpression of either ICER I or II $\gamma$  represses the uninduced level of gene expression from all CRE containing promoters examined in the present study. This indicates that endogenous ICER levels in the uninduced state are not sufficiently high to completely silence the basal expression from these promoters.

#### Overexpression of ICER I and II $\gamma$ Proteins did not Effect Cell Growth


Razavi et al. [1998] have shown that ICER II $\gamma$  dramatically inhibits the growth and DNA synthesis of mouse pituitary tumor cells and human choriocarcinoma cells, while Memin

et al. [2002] found that overexpression of ICER II $\gamma$  in prostate tumor AT6.3 cells did not affect cell growth. We examined the effect of ICER I and II $\gamma$  overexpression on the proliferation of HEK 293 cells, by comparing BrdU-incorporation in cells cultivated in the absence of tetracycline with BrdU-incorporation in cells cultivated in the presence of tetracycline. We found no significant differences in cell proliferation in the presence or absence of high levels of either ICER I or II $\gamma$ , indicating that neither of these splice variants affects normal growth in HEK 293 cells (Fig. 8A–C). Taken together with the results reported by others [Razavi et al., 1998; Memin et al., 2002], our results indicate that the influence of ICER on growth is cell type specific.

#### DISCUSSION

The majority of all human genes are alternatively spliced [Black, 2003], and the biological activities of different splice variant products of






**Fig. 6.** Effect of ICER siRNAs on CRE-driven gene activity. Results are shown as % of forskolin response in absence of tetracycline. **A:** HEK 293<sub>ind</sub>-ICER I cells **(B)** HEK 293<sub>ind</sub>-ICER II<sub>γ</sub> cells, and **(C)** HEK 293<sub>ind</sub>-Control cells were transfected with pCRELuc and siRNA-ICER I (specifically targeting ICER I), siRNA-ICER II<sub>γ</sub> (specifically targeting ICER II<sub>γ</sub>), siRNA-All-ICER (targeting all ICER splice variants) or siRNA-CAT, pretreated with tetracycline (1 μg/ml) for 24 h, and treated with forskolin (10 μM) for 6 h. Results are shown as mean ± SD (n = 6), and the graph is representative of two separated experiments.

the same gene are often dissimilar as a result of particular domains being present in the protein or not. Splice events can transform membrane-bound proteins into soluble proteins, as is the case for the fibroblast growth factor receptors (FGFR) [Jang, 2002]. Changes in splicing of genes like CD44, the Wilms' tumor gene WT1, variants of BRCA1 and BRCA2, MDM2, FGFR, kallikrein family members, and a large number of other genes, may occur during tumor progression and this has been suggested to play an important role in carcinogenesis [Brinkman, 2004]. For the vast majority of alternative splice events their biological significance is still unclear. In order to understand why several ICER splice variants exist, it is of interest to characterize the role of each splice variant, and thus, each variant has to be studied explicitly. We have used cell systems where the level of overexpression of each of the splice variants ICER I and II<sub>γ</sub> is controlled and separated from other cellular events. These cell systems thus enable us to study each of the two splice variants separately, with respect to their roles in transcription regulation and proliferation. Our


results show that both splice variants repress CRE-driven transcription in a similar manner and that none of them seem to interfere with HEK 293 cell growth. So far there have been few reports characterizing biological differences between ICER splice variants, and studies that involve more than one splice variant have not detected differences in biological functions [Molina et al., 1993; Barabitskaja and Foulke, 2006]. Inada et al. [1999] shows that ICER I as well as ICER I<sub>γ</sub> splice variants, both of which contain the DNA binding domain I (DBD I) (Fig. 1) act as repressors of the insulin promoter. Another study has reported that all four ICER splice variants bind to the inhibin α subunit CRE-element with similar affinities, and demonstrated that ICER splice variants are all capable of significantly downregulating both basal and forskolin-induced activity of the inhibin α subunit promoter, independent on whether they contain the alternative DNA binding domains DBD I or DBD II (Fig. 1) [Burkart et al., 2006]. Our findings indicate that the two ICER splice variants comprising either DBD I (ICER I) or DBD II



**Fig. 7.** Effect of ICER overexpression on AP1 and NF $\kappa$ B reporter gene. **A:** HEK 293<sub>ind</sub>-ICER I and HEK 293<sub>ind</sub>-ICER II $\gamma$  cells were transfected with pAP1-Luc, and 16 h before lysis pretreated with tetracycline (1  $\mu$ g/ml), and treated with Forskolin (10 M) and/or PMA (50 ng/ $\mu$ l) for 6 h. Mean  $\pm$  SEM of triple measurements are shown. **B:** HEK 293<sub>ind</sub>-ICER I and HEK 293<sub>ind</sub>-ICER II $\gamma$  were transfected with NF $\kappa$ B-Luc, and 16 h before lysis pretreated with tetracycline (1  $\mu$ g/ml), and treated with rhTNF $\alpha$  (20 ng/ml) for 6 h. Results are shown as mean  $\pm$  SD (n = 3), and are representative of three independent experiments.

(ICER II $\gamma$ ) display similar repressive effects on transcription, which is in accordance with the earlier findings.

The c-fos proto-oncogene is known to play a key role in the control of intracellular events leading to cell proliferation, cell differentiation or apoptosis [Holt et al., 1986; Nishikura and Murray, 1987; Hu et al., 1996; Preston et al., 1996]. We have recently found that endogenous ICER suppresses gastrin-mediated transcriptional activation of c-fos in the rat neuroendocrine cell line AR42J [Steigedal et al., 2006]. In the present study we show that both ICER I and II $\gamma$  repress PACAP- and forskolin-induced c-fos gene expression in HEK 293 cells. In accordance with our findings, c-fos is reported to be repressed in ICER II $\gamma$  overexpressing AtT20 cells [Razavi et al., 1998]. ICER II $\gamma$  has previously been described as a tumor suppressor [Razavi et al., 1998]. Since we found



**Fig. 8.** Effect of acute ICER overexpression on proliferation in HEK 293<sub>ind</sub> cells. **A:** HEK 293<sub>ind</sub>-ICER I cells (**B**) HEK 293<sub>ind</sub>-ICER II $\gamma$  cells, and (**C**) HEK 293<sub>ind</sub>-Control cells were treated or not treated with tetracycline for 5 days, and proliferation measured by BrdU incorporation. Values shown are mean  $\pm$  SD (n = 5). Similar results have been obtained in two independent experiments.

that the repressive effect of ICER I on c-fos is comparable to that of ICER II $\gamma$ , and since we show that both ICER I and II $\gamma$  specifically target CRE which is crucial for transcriptional activation of the c-fos promoter [Thommesen et al., 2001; Tenbrock et al., 2006], our study indicates that also ICER I may act as an anti-oncogene inhibiting the expression of growth-related genes like c-fos, and that both ICER I and II $\gamma$  might thereby function to inhibit the proliferate effect of mediators like PACAP.

Throughout the neuroendocrine system, CgA is a ubiquitous component of secretory vesicles wherein it may be stored and released together with a number of polypeptide hormones [Taupe-not et al., 2003]. The CRE domain in the CgA promoter responds to cAMP [Wu et al., 1995], and plays a crucial role in neuroendocrine cell type-specific expression of this protein in response to, for example, PACAP which activates CgA gene transcription via PKA [Taupe-not et al., 1998]. Our results showing that both ICER I and II $\gamma$  can modulate cAMP-activated CgA gene expression indicate that ICER may function as a negative feedback inhibitor in CgA synthesis induced by mediators like PACAP. The fact that no biological differences were observed between the splice variants ICER I and II $\gamma$  in their repression of CRE-driven transcription may indicate that putative different biological functions of the splice variants are not manifested as differences in protein function, but may rather be related to differences in their expression levels in given biological situations, and in specific cell types. ICER is known to form heterodimers with other CREM, CREB, or ATF1 proteins [Molina et al., 1993; Gellersen et al., 1997]. Thus, the splice variants may differ with respect to which transcription factor they interact with. Alternatively, heterodimers with the same non-ICER partner but with different ICER splice variants may exhibit dissimilar biological activities. Moreover, ICER splice variants may differ in their repressing effect depending on the context in which the CRE promoter element is located. It has been shown that cAMP-induced gene expression mediated by CREB changes when sequence and location of the CRE in the promoter is varied [Mao et al., 1998; Mayr and Montminy, 2001]. This might be the case for ICER as well, that is, the localization and context of the CRE element may be important for the ICER effect. Further studies should

address questions whether different ICERs have different repressing activity depending on the promoter sequence, that is, whether it contains a consensus CRE or a CRE-like sequence [Bodor and Habener, 1998; Wang and Murphy, 2000], in order to increase our knowledge of biological functions of ICER splice variants.

## ACKNOWLEDGMENTS

We thank Dr. Ole Morten Seternes for the pGEMA plasmid, Dr. Daniel O'Connor for the pXp100Luc plasmid and Dr. Mohammed Amarzguioui for help with designing siRNA-ICER I and siRNA-ICER II $\gamma$ .

## REFERENCES

- Amarzguioui M, Prydz H. 2004. An algorithm for selection of functional siRNA sequences. *Biochem Biophys Res Commun* 316:1050–1058.
- Amarzguioui M, Holen T, Babaie E, Prydz H. 2003. Tolerance for mutations and chemical modifications in a siRNA. *Nucleic Acids Res* 31:589–595.
- Barabitskaja O, Foulke JS, Jr., Pati S, Bodor J, Reitz MS, Jr. 2006. Suppression of MIP-1{beta} transcription in human T cells is regulated by inducible cAMP early repressor (ICER). *J Leukoc Biol* 79:378–387.
- Berkowitz LA, Riabowol KT, Gilman MZ. 1989. Multiple sequence elements of a single functional class are required for cyclic AMP responsiveness of the mouse c-fos promoter. *Mol Cell Biol* 9:4272–4281.
- Black DL. 2003. Mechanisms of alternative pre-messenger RNA splicing. *Annu Rev Biochem* 72:291–336.
- Bodor J, Habener JF. 1998. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes. *J Biol Chem* 273:9544–9551.
- Bokar JA, Roesler WJ, Vandebark GR, Kaetzel DM, Hanson RW, Nilson JH. 1988. Characterization of the cAMP responsive elements from the genes for the alpha-subunit of glycoprotein hormones and phosphoenolpyruvate carboxykinase (GTP). Conserved features of nuclear protein binding between tissues and species. *J Biol Chem* 263:19740–19747.
- Brinkman BM. 2004. Splice variants as cancer biomarkers. *Clin Biochem* 37:584–594.
- Burkart AD, Mukherjee A, Mayo KE. 2006. Mechanism of repression of the inhibin alpha-subunit gene by inducible 3',5'-cyclic adenosine monophosphate early repressor. *Mol Endocrinol* 20:584–597.
- Daniel PB, Rohrbach L, Habener JF. 2000. Novel cyclic adenosine 3',5'-monophosphate (cAMP) response element modulator theta isoforms expressed by two newly identified cAMP-responsive promoters active in the testis. *Endocrinology* 141:3923–3930.
- De Cesare D, Sassone-Corsi P. 2000. Transcriptional regulation by cyclic AMP-responsive factors. *Prog Nucleic Acid Res Mol Biol* 64:343–369.

- De Cesare D, Fimia GM, Brancorsini S, Parvinen M, Sassone-Corsi P. 2003. Transcriptional control in male germ cells: General factor TFIIA participates in CREM-dependent gene activation. *Mol Endocrinol* 17:2554–2565.
- Delmas V, Laoide BM, Masquillier D, de Groot RP, Foulkes NS, Sassone-Corsi P. 1992. Alternative usage of initiation codons in mRNA encoding the cAMP-responsive-element modulator generates regulators with opposite functions. *Proc Natl Acad Sci USA* 89:4226–4230.
- Fisch TM, Prywes R, Simon MC, Roeder RG. 1989. Multiple sequence elements in the c-fos promoter mediate induction by cAMP. *Genes Dev* 3:198–211.
- Foulkes NS, Borrelli E, Sassone-Corsi P. 1991. CREM gene: Use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. *Cell* 64:739–749.
- Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P. 1996. Transcriptional control of circadian hormone synthesis via the CREM feedback loop. *Proc Natl Acad Sci USA* 93:14140–14145.
- Gellersen B, Kempf R, Telgmann R. 1997. Human endometrial stromal cells express novel isoforms of the transcriptional modulator CREM and up-regulate ICER in the course of decidualization. *Mol Endocrinol* 11:97–113.
- Holt JT, Gopal TV, Moulton AD, Nienhuis AW. 1986. Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. *Proc Natl Acad Sci USA* 83:4794–4798.
- Hu L, Hatano M, Ruther U, Tokuhisa T. 1996. Overexpression of c-Fos induces apoptosis of CD43+ pro-B cells. *J Immunol* 157:3804–3811.
- Inada A, Someya Y, Yamada Y, Ihara Y, Kubota A, Ban N, Watanabe R, Tsuda K, Seino Y. 1999. The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID. *J Biol Chem* 274:21095–21103.
- Inada A, Hamamoto Y, Tsuura Y, Miyazaki J, Toyokuni S, Ihara Y, Nagai K, Yamada Y, Bonner-Weir S, Seino Y. 2004. Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells. *Mol Cell Biol* 24:2831–2841.
- Inada A, Nagai K, Arai H, Miyazaki J, Nomura K, Kanamori H, Toyokuni S, Yamada Y, Bonner-Weir S, Weir GC, Fukatsu A, Seino Y. 2005. Establishment of a diabetic mouse model with progressive diabetic nephropathy. *Am J Pathol* 167:327–336.
- Jang JH. 2002. Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. *Biochem Biophys Res Commun* 292:378–382.
- Jaworski J, Mioduszevska B, Sanchez-Capelo A, Figiel I, Habas A, Gozdz A, Proszynski T, Hetman M, Mallet J, Kaczmarek L. 2003. Inducible cAMP early repressor, an endogenous antagonist of cAMP responsive element-binding protein, evokes neuronal apoptosis in vitro. *J Neurosci* 23:4519–4526.
- Kienlen Campard P, Crochemore C, Rene F, Monnier D, Koch B, Loeffler JP. 1997. PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. *DNA Cell Biol* 16:323–333.
- Kim KS, Lee MK, Carroll J, Joh TH. 1993. Both the basal and inducible transcription of the tyrosine hydroxylase gene are dependent upon a cAMP response element. *J Biol Chem* 268:15689–15695.
- Lamas M, Molina C, Foulkes NS, Jansen E, Sassone-Corsi P. 1997. Ectopic ICER expression in pituitary corticotroph AtT20 cells: Effects on morphology, cell cycle, and hormonal production. *Mol Endocrinol* 11:1425–1434.
- Laoide BM, Foulkes NS, Schlotter F, Sassone-Corsi P. 1993. The functional versatility of CREM is determined by its modular structure. *EMBO J* 12:1179–1191.
- Lewis EJ, Harrington CA, Chikaraishi DM. 1987. Transcriptional regulation of the tyrosine hydroxylase gene by glucocorticoid and cyclic AMP. *Proc Natl Acad Sci USA* 84:3550–3554.
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402–408.
- Mao D, Warner EA, Gurwirth SA, Dowd DR. 1998. Differential regulation and transcriptional control of immediate early gene expression in forskolin-treated WE HI7.2 thymoma cells. *Mol Endocrinol* 12:492–503.
- Mayr B, Montminy M. 2001. Transcriptional regulation by the phosphorylation-dependent factor CREB. *Nat Rev Mol Cell Biol* 2:599–609.
- Memin E, Yehia G, Razavi R, Molina CA. 2002. ICER reverses tumorigenesis of rat prostate tumor cells without affecting cell growth. *Prostate* 53:225–231.
- Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P. 1993. Inducibility and negative autoregulation of CREM: An alternative promoter directs the expression of ICER, an early response repressor. *Cell* 75:875–886.
- Montminy MR, Sevarino KA, Wagner JA, Mandel G, Goodman RH. 1986. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc Natl Acad Sci USA* 83:6682–6686.
- Mousses S, Caplen NJ, Cornelison R, Weaver D, Basik M, Hautaniemi S, Elkhoulou AG, Lotufo RA, Choudary A, Dougherty ER, Suh E, Kallioniemi O. 2003. RNAi microarray analysis in cultured mammalian cells. *Genome Res* 13:2341–2347.
- Nakajima T, Uchida C, Anderson SF, Parvin JD, Montminy M. 1997. Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors. *Genes Dev* 11:738–747.
- Nishikura K, Murray JM. 1987. Antisense RNA of proto-oncogene c-fos blocks renewed growth of quiescent 3T3 cells. *Mol Cell Biol* 7:639–649.
- Preston GA, Lyon TT, Yin Y, Lang JE, Solomon G, Annab L, Srinivasan DG, Alcorta DA, Barrett JC. 1996. Induction of apoptosis by c-Fos protein. *Mol Cell Biol* 16:211–218.
- Quinn PG. 2002. Mechanisms of basal and kinase-inducible transcription activation by CREB. *Prog Nucleic Acid Res Mol Biol* 72:269–305.
- Razavi R, Ramos JC, Yehia G, Schlotter F, Molina CA. 1998. ICER-IIgamma is a tumor suppressor that mediates the antiproliferative activity of cAMP. *Oncogene* 17:3015–3019.
- Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X, Bertherat J. 2002. Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. *Ann NY Acad Sci* 968:65–74.



- Schafer H, Zheng J, Gundlach F, Gunther R, Siegel EG, Folsch UR, Schmidt WE. 1996. Pituitary adenylate cyclase-activating polypeptide stimulates proto-oncogene expression and activates the AP-1 (c-Fos/c-Jun) transcription factor in AR4-2J pancreatic carcinoma cells. *Eur J Biochem* 242:467–476.
- Servillo G, Della Fazio MA, Sassone-Corsi P. 2002. Coupling cAMP signaling to transcription in the liver: Pivotal role of CREB and CREM. *Exp Cell Res* 275:143–154.
- Short JM, Wynshaw-Boris A, Short HP, Hanson RW. 1986. Characterization of the phosphoenolpyruvate carboxylase (GTP) promoter-regulatory region. II. Identification of cAMP and glucocorticoid regulatory domains. *J Biol Chem* 261:9721–9726.
- Stehle JH, Foulkes NS, Molina CA, Simonneaux V, Pevet P, Sassone-Corsi P. 1993. Adrenergic signals direct rhythmic expression of transcriptional repressor CREM in the pineal gland. *Nature* 365:314–320.
- Steigedal TS, Bruland T, Misund K, Thommesen L, Lægreid A. 2006. Inducible cAMP early repressor (ICER) suppresses gastrin-mediated activation of cyclin D1 and c-fos gene expression. *Am J Physiol* (in press).
- Sun P, Maurer RA. 1995. An inactivating point mutation demonstrates that interaction of cAMP response element binding protein (CREB) with the CREB binding protein is not sufficient for transcriptional activation. *J Biol Chem* 270:7041–7044.
- Taupenot L, Mahata SK, Wu H, O'Connor DT. 1998. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylate cyclase-activating polypeptide (PACAP). *J Clin Invest* 101:863–876.
- Taupenot L, Harper KL, O'Connor DT. 2003. The chromogranin-secretogranin family. *N Engl J Med* 348:1134–1149.
- Tenbrock K, Juang YT, Leukert N, Roth J, Tsokos GC. 2006. The transcriptional repressor cAMP response element modulator alpha interacts with histone deacetylase 1 to repress promoter activity. *J Immunol* 177: 6159–6164.
- Thommesen L, Norsett K, Sandvik AK, Hofslie E, Lægreid A. 2000. Regulation of inducible cAMP early repressor expression by gastrin and cholecystokinin in the pancreatic cell line AR42J. *J Biol Chem* 275:4244–4250.
- Thommesen L, Hofslie E, Paulssen RH, Anthonsen MW, Lægreid A. 2001. Molecular mechanisms involved in gastrin-mediated regulation of cAMP-responsive promoter elements. *Am J Physiol Endocrinol Metab* 281: E1316–E1325.
- Thommesen L, Stunes AK, Monjo M, Grosvik K, Tambur-stuen MV, Kjobli E, Lyngstadaas SP, Reseland JE, Syversen U. 2006. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. *J Cell Biochem* 99:824–834.
- Tomita H, Nazmy M, Kajimoto K, Yehia G, Molina CA, Sadoshima J. 2003. Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation. *Circ Res* 93:12–22.
- Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H. 1998. Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. *Neuroscience* 84:801–812.
- Wang X, Murphy TJ. 2000. The inducible cAMP early repressor ICER1gamma inhibits CREB and AP-1 transcription but not AT1 receptor gene expression in vascular smooth muscle cells. *Mol Cell Biochem* 212: 111–119.
- Wu H, Mahata SK, Mahata M, Webster NJ, Parmer RJ, O'Connor DT. 1995. A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A. *J Clin Invest* 96:568–578.